Atlas Venture Associates Ix, LLC Intellia Therapeutics, Inc. Transaction History
Atlas Venture Associates Ix, LLC
- $11.3 Million
- Q3 2023
A detailed history of Atlas Venture Associates Ix, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Atlas Venture Associates Ix, LLC holds 10,000 shares of NTLA stock, worth $179,899. This represents 2.81% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$179,899
Previous $407,000
22.36%
% of portfolio
2.81%
Previous 2.23%
Shares
6 transactions
Others Institutions Holding NTLA
# of Institutions
326Shares Held
88.8MCall Options Held
673KPut Options Held
865K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.6MShares$209 Million2.36% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$173 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.1MShares$164 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.8MShares$86.4 Million3.53% of portfolio
-
State Street Corp Boston, MA4.36MShares$78.5 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.37B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...